论文部分内容阅读
骨是许多类型实体瘤转移的首选位置,而肿瘤骨转移后则能导致产生显著的骨骼疾病、包括骨痛、病理性骨折、脊髓压迫和高血钙症等。另外,肿瘤治疗的不断进步已使肿瘤患者的存活期有了相当改善,尽管不少肿瘤治疗方案本身也存在会致骨丢失的副作用。比如,乳腺癌和前列腺癌的激素修饰疗法可导致显著骨丢失并由此提高患者的骨折风险。随着肿瘤治疗进步及肿瘤患者存活期延长,肿瘤患者的骨骼健康管理问题已经显得日趋重要,因为预防和治疗骨骼并发症能够潜在改善各类肿瘤及其不同阶段患者的临床结果与生活质量。本文简要、概括地描述二膦酸盐类药物在肿瘤骨转移和肿瘤治疗相关骨丢失防治中作用的临床研究进展。
Bone is the preferred location for the metastasis of many types of solid tumors, which can lead to significant skeletal disease after bone metastases, including bone pain, pathological fractures, spinal cord compression and hypercalcemia. In addition, advances in cancer treatment have led to a considerable improvement in the survival of cancer patients, although many of the cancer treatment options also have the side effects of losing bone. For example, hormone modifying therapies for breast and prostate cancer can result in significant bone loss and thereby increase the risk of fracture in patients. With advances in cancer treatment and survival of cancer patients, the issue of bone health management in cancer patients has become increasingly important as prevention and treatment of bone complications can potentially improve the clinical outcome and quality of life in various types of tumors and their different stages. This article briefly summarizes the progress of clinical research on the role of bisphosphonates in the prevention and treatment of bone metastases associated with tumor metastasis and tumor therapy.